September II 2025

Explore the latest advancements in muscle-invasive bladder cancer treatment, including immunotherapy and novel therapies enhancing patient outcomes.

Emerging CAR T-cell therapies, like DuoCAR20.19.22-D95, show promise in overcoming challenges in treating relapsed B-cell malignancies.

Explore the latest advancements in DLL3-targeted therapies for small cell lung cancer, showcasing promising trial results and treatment options.

Adoptive cell therapy with tumor-infiltrating lymphocytes shows promise for advanced melanoma patients unresponsive to existing treatments, offering tailored immunotherapy options.

Oncologists explore advanced treatment options for ROS1-positive non-small cell lung cancer, highlighting improved efficacy and personalized therapy choices.

Roy S. Herbst discusses advancements in EGFR-targeted therapies for early-stage NSCLC, highlighting improved survival rates and the role of molecular residual disease.

Innovative treatments like JAK2 inhibitors and bispecific antibodies show promise in overcoming immunotherapy resistance in non-small cell lung cancer.

Innovative CAR-iNKT cell therapy shows promise in improving outcomes for acute myeloid leukemia, offering cost-effective and potent treatment options.

Physicians enhance patient care through intentional listening, fostering trust, and connection while combating burnout and improving communication in healthcare.

Recent studies highlight the potential of minimal residual disease (MRD) testing to influence treatment decisions in multiple myeloma and chronic lymphocytic leukemia.